Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-11
2005-01-11
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S082000, C546S084000
Reexamination Certificate
active
06841556
ABSTRACT:
Compounds of the formula Iare suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases whose course involves an increased activity of NIK.
REFERENCES:
patent: 4748246 (1988-05-01), Skotnicki et al.
patent: 1134221 (2001-09-01), None
patent: 2185255 (1987-01-01), None
patent: 2185255 (1987-07-01), None
patent: WO 0244153 (2002-06-01), None
patent: WO 03024936 (2003-03-01), None
Lucia Cecchi et al., Synthesis of 1,5-Diaryl-3-Methyl-1 H-pyrazolo[4,5-c] Isoquinolines And Studies of Binding to Specific Peripheral Benzodiazepine Binding Sites, Journal of Pharmaceutical Sciences (1989, pp. 437-442, vol. 78, No. 6).
Yumi Yamamoto et al., Role of the NF-κB Pathway in the Pathogenesis of Human Disease States, Current Molecular Medicine (2001, pp. 287-296, vol. 1).
Flohr Stefanie
Naumann Thorsten
Aventis Pharma Deutschland GmbH
Gupta Balaram
Seaman D. Margaret
LandOfFree
Pyrazoloisoquinoline derivatives for inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazoloisoquinoline derivatives for inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazoloisoquinoline derivatives for inhibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3382901